StreetInsider.com News Articles

Haemonetics (HAE) PT Raised to $90 at Mizuho

Wed, 15 Jul 2026 06:39:59 -0400

Mizuho analyst Anthony Petrone raised the price target on Haemonetics (NYSE: HAE) to $90.00 (from $85.00) while maintaining a Outperform rating.

U.S. MedTech stocks: Q2 earnings preview

Sun, 12 Jul 2026 10:00:00 -0400

At current valuations, MedTech stocks might have hit bottom, Citi analysts suggest, as they preview Q2 earnings of names under the firm’s coverage, with the upcoming season expected to reflect well-understood challenges, though the analysts believe things could look up from here for select stocks.

The focus has shifted to what could go right rather than evaluating what has gone wrong, they said. “We find investors looking forward, not just to the 2Q or 2H but to 2027+, as we move from diagnosing the patient to healing it.”

While the P/E multiple of the S&P Equipment and Supplies (E&S) index declined to

U.S. MedTech stocks: Q2 earnings preview

Sun, 12 Jul 2026 10:00:00 -0400

While the P/E multiple of the S&P Equipment and Supplies (E&S) index declined to

U.S. MedTech stocks: Q2 earnings preview

Sun, 12 Jul 2026 10:00:00 -0400

While the P/E multiple of the S&P Equipment and Supplies (E&S) index declined to

U.S. MedTech stocks: Q2 earnings preview

Sun, 12 Jul 2026 10:00:00 -0400

While the P/E multiple of the S&P Equipment and Supplies (E&S) index declined to

U.S. MedTech stocks: Q2 earnings preview

Sun, 12 Jul 2026 10:00:00 -0400

While the P/E multiple of the S&P Equipment and Supplies (E&S) index declined to

U.S. MedTech stocks: Q2 earnings preview

Sun, 12 Jul 2026 10:00:00 -0400

While the P/E multiple of the S&P Equipment and Supplies (E&S) index declined to

U.S. MedTech stocks: Q2 earnings preview

Sun, 12 Jul 2026 10:00:00 -0400

While the P/E multiple of the S&P Equipment and Supplies (E&S) index declined to

U.S. MedTech stocks: Q2 earnings preview

Sun, 12 Jul 2026 10:00:00 -0400

While the P/E multiple of the S&P Equipment and Supplies (E&S) index declined to

U.S. MedTech stocks: Q2 earnings preview

Sun, 12 Jul 2026 10:00:00 -0400

While the P/E multiple of the S&P Equipment and Supplies (E&S) index declined to

U.S. MedTech stocks: Q2 earnings preview

Sun, 12 Jul 2026 10:00:00 -0400

While the P/E multiple of the S&P Equipment and Supplies (E&S) index declined to

U.S. MedTech stocks: Q2 earnings preview

Sun, 12 Jul 2026 10:00:00 -0400

While the P/E multiple of the S&P Equipment and Supplies (E&S) index declined to

U.S. MedTech stocks: Q2 earnings preview

Sun, 12 Jul 2026 10:00:00 -0400

While the P/E multiple of the S&P Equipment and Supplies (E&S) index declined to

U.S. MedTech stocks: Q2 earnings preview

Sun, 12 Jul 2026 10:00:00 -0400

While the P/E multiple of the S&P Equipment and Supplies (E&S) index declined to

U.S. MedTech stocks: Q2 earnings preview

Sun, 12 Jul 2026 10:00:00 -0400

While the P/E multiple of the S&P Equipment and Supplies (E&S) index declined to

Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026

Wed, 08 Jul 2026 16:05:00 -0400

BOSTON, July 8, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish first quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, August 6, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on August 6, 2026.

The call can be accessed via teleconference at: Q1 2027 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN

Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026

Wed, 08 Jul 2026 16:05:00 -0400

Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026

Wed, 08 Jul 2026 16:05:00 -0400

Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026

Wed, 08 Jul 2026 16:05:00 -0400

Citi Adds Four Names to Catalyst Call List

Wed, 08 Jul 2026 05:46:08 -0400

(Updated - July 8, 2026 5:46 AM EDT)

Citi Adds Four Names to Catalyst Call List.

Adds:
- 90-Day Upside Catalyst Watch on Intuitive Surgical (NASDAQ: ISRG), Charles River Laboratories (NYSE: CRL), and GE HealthCare (NASDAQ: GEHC).
- 90-Day Downside Catalyst Watch on Haemonetics (NYSE: HAE)

Citi Adds Four Names to Catalyst Call List

Wed, 08 Jul 2026 05:46:08 -0400

(Updated - July 8, 2026 5:46 AM EDT)

Citi Adds Four Names to Catalyst Call List.

Adds:
- 90-Day Upside Catalyst Watch on Intuitive Surgical (NASDAQ: ISRG), Charles River Laboratories (NYSE: CRL), and GE HealthCare (NASDAQ: GEHC).
- 90-Day Downside Catalyst Watch on Haemonetics (NYSE: HAE)

Citi Adds Four Names to Catalyst Call List

Wed, 08 Jul 2026 05:46:08 -0400

(Updated - July 8, 2026 5:46 AM EDT)

Citi Adds Four Names to Catalyst Call List.

Adds:
- 90-Day Upside Catalyst Watch on Intuitive Surgical (NASDAQ: ISRG), Charles River Laboratories (NYSE: CRL), and GE HealthCare (NASDAQ: GEHC).
- 90-Day Downside Catalyst Watch on Haemonetics (NYSE: HAE)

Citi Adds Four Names to Catalyst Call List

Wed, 08 Jul 2026 05:46:08 -0400

(Updated - July 8, 2026 5:46 AM EDT)

Citi Adds Four Names to Catalyst Call List.

Adds:
- 90-Day Upside Catalyst Watch on Intuitive Surgical (NASDAQ: ISRG), Charles River Laboratories (NYSE: CRL), and GE HealthCare (NASDAQ: GEHC).
- 90-Day Downside Catalyst Watch on Haemonetics (NYSE: HAE)

BTIG Reiterates Buy Rating on Haemonetics (HAE)

Fri, 26 Jun 2026 05:45:19 -0400

BTIG analyst Marie Thibault reiterated a Buy rating and $64.00 price target on Haemonetics (NYSE: HAE).

The analyst commented: "Earlier this week, we hosted Haemonetics CFO James D'Arecca, VP of Investor Relations and Treasury Olga Guyette, and Investor Relations Manager David Trenk for investor meetings in NYC. Conversations were centered on Plasma and Interventional Technologies (IVT), with discussions detailing historical drivers, the set-up for FY2027, and how to think about potential upside to guidance assumptions. On Plasma, key topics included the opportunity for a pricing benefit from the Persona Plus rollout, the conservatism embedded in the 0%-2% collection volume growth guide,

Haemonetics (HAE) PT Raised to $85 at Mizuho

Mon, 15 Jun 2026 06:39:41 -0400

(Updated - June 15, 2026 6:39 AM EDT)

Mizuho analyst Anthony Petrone raised the price target on Haemonetics (NYSE: HAE) to $85.00 (from $70.00) while maintaining a Outperform rating.

The analyst commented: "We have been fielding consistent in-bounds on HAE (OP) out-performance since mid-May, as shares have surged +46% vs +3.5% for the S&P 500 over that time. We credit the strong rebound in shares over the past several weeks to evidence that the end-market for intravenous immunoglobulin (Ig) products (the key driver to the company's plasma-collection business) remains healthy coupled with its NexSys system still performing better than competition in the